PITTSBURGH, Dec 12, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for levofloxacin tablets in 250 mg and 500 mg strengths.

Levoflaxacin is the generic version of Ortho McNeil Pharmaceutical Inc.'s Levaquin^® Tablets.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE: Mylan Laboratories Inc.

FOR: Mylan Laboratories Inc.
Kris King, 724-514-1800

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.